By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Point-of-care firm SuperNova Diagnostics today announced a co-marketing deal with Concile for a test that assesses "various deficiencies" relating to wellness and chronic diseases.

The terms of the deal gives Concile, a German diagnostic development and distribution firm, the rights to co-market SuperNova's test in Europe. SuperNova will develop and manufacture the test, secure regulatory approvals, and co-market it.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.